Narjust Duma1, Kelly C Gast2, Grace M Choong2, Roberto A Leon-Ferre1, Ciara C O'Sullivan3. 1. Division of Medical Oncology, Mayo Clinic, Rochester, MN, 55905, USA. 2. Department of Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA. 3. Division of Medical Oncology, Mayo Clinic, Rochester, MN, 55905, USA. OSullivan.Ciara@mayo.edu.
Abstract
PURPOSE OF REVIEW: To provide an overview of the clinical development of poly(ADP-ribose) polymerase inhibitors (PARPi) in breast cancer to date and to review existing challenges and future research directions. RECENT FINDINGS: We summarize the clinical development of PARPi in breast cancer from bench to bedside, and discuss the results of recent phase 3 trials in patients with metastatic breast cancer (MBC) and germline mutations in BRCA1/2 (gBRCAm). We will also provide an update regarding mechanisms of action and resistance to PARPi, and review clinical trials of PARPi as monotherapy or in combination regimens. PARPi are a novel treatment approach in persons with gBRCA1/2m-associated MBC. Going forward, the clinical applicability of these compounds outside the gBRCAm setting will be studied in greater detail. The identification of accurate predictive biomarkers of response is a research priority.
PURPOSE OF REVIEW: To provide an overview of the clinical development of poly(ADP-ribose) polymerase inhibitors (PARPi) in breast cancer to date and to review existing challenges and future research directions. RECENT FINDINGS: We summarize the clinical development of PARPi in breast cancer from bench to bedside, and discuss the results of recent phase 3 trials in patients with metastatic breast cancer (MBC) and germline mutations in BRCA1/2 (gBRCAm). We will also provide an update regarding mechanisms of action and resistance to PARPi, and review clinical trials of PARPi as monotherapy or in combination regimens. PARPi are a novel treatment approach in persons with gBRCA1/2m-associated MBC. Going forward, the clinical applicability of these compounds outside the gBRCAm setting will be studied in greater detail. The identification of accurate predictive biomarkers of response is a research priority.
Entities:
Keywords:
BRCA1/2 mutations; BRCAness; PARP inhibitors; Poly(ADP-ribose) polymerases; Triple-negative breast cancer
Authors: Tomoe Higuchi; Dallas B Flies; Nicole A Marjon; Gina Mantia-Smaldone; Lukas Ronner; Phyllis A Gimotty; Sarah F Adams Journal: Cancer Immunol Res Date: 2015-07-02 Impact factor: 11.151
Authors: Otto Metzger-Filho; Andrew Tutt; Evandro de Azambuja; Kamal S Saini; Giuseppe Viale; Sherene Loi; Ian Bradbury; Judith M Bliss; Hatem A Azim; Paul Ellis; Angelo Di Leo; José Baselga; Christos Sotiriou; Martine Piccart-Gebhart Journal: J Clin Oncol Date: 2012-03-26 Impact factor: 44.544
Authors: Louise J Barber; Shahneen Sandhu; Lina Chen; James Campbell; Iwanka Kozarewa; Kerry Fenwick; Ioannis Assiotis; Daniel Nava Rodrigues; Jorge S Reis Filho; Victor Moreno; Joaquin Mateo; L Rhoda Molife; Johann De Bono; Stan Kaye; Christopher J Lord; Alan Ashworth Journal: J Pathol Date: 2013-02 Impact factor: 7.996
Authors: V Abkevich; K M Timms; B T Hennessy; J Potter; M S Carey; L A Meyer; K Smith-McCune; R Broaddus; K H Lu; J Chen; T V Tran; D Williams; D Iliev; S Jammulapati; L M FitzGerald; T Krivak; J A DeLoia; A Gutin; G B Mills; J S Lanchbury Journal: Br J Cancer Date: 2012-10-09 Impact factor: 7.640
Authors: Kirsten M Timms; Victor Abkevich; Elisha Hughes; Chris Neff; Julia Reid; Brian Morris; Saritha Kalva; Jennifer Potter; Thanh V Tran; Jian Chen; Diana Iliev; Zaina Sangale; Eliso Tikishvili; Michael Perry; Andrey Zharkikh; Alexander Gutin; Jerry S Lanchbury Journal: Breast Cancer Res Date: 2014-12-05 Impact factor: 6.466